 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

MaxCyte appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

ROCKVILLE, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

Rathbones Group PLC cut its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT  Free Report) by 1.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 362,584 shares of the companys stock after selling 5,004 ...

Rathbones Group PLC Sells 5,004 Shares of MaxCyte, Inc. (NASDAQ:MXCT)

Barclays PLC grew its position in shares of MaxCyte, Inc. (NASDAQ:MXCT  Free Report) by 154.5% during the first quarter, Holdings Channel reports. The firm owned 77,878 shares of the...

MaxCyte, Inc. (NASDAQ:MXCT) Shares Bought by Barclays PLC

Investors eyeing a purchase of MaxCyte Inc (MXCT) stock, but tentative about paying the going market price of 3.56/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the April 2024 put at the &#36...

Commit To Buy MaxCyte At $2.50, Earn 9.2% Annualized Using Options

Bank of New York Mellon Corp trimmed its holdings in shares of MaxCyte, Inc. (NASDAQ:MXCT  Free Report) by 1.3% in the first quarter, according to the company in its most recent filing with...

Bank of New York Mellon Corp Cuts Holdings in MaxCyte, Inc. (NASDAQ:MXCT)

MaxCyte, Inc. (NASDAQ:MXCT  Free Report)  Stock analysts at William Blair reduced their Q3 2023 earnings per share (EPS) estimates for shares of MaxCyte in a report issued on...

Q3 2023 Earnings Estimate for MaxCyte, Inc. Issued By William Blair (NASDAQ:MXCT)

MaxCyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance ROCKVILLE, MD, August 9, 2023 MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell...

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

ROCKVILLE, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development ...

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. Its propriety cell therapy is used in drug discovery and development, and biomanufacturing. Its products include ATx, STx, and GTx instruments. The company was founded by Douglas A. Doerfler on July 31, 1998 and is headquartered in Rockville, MD.

Watchers	317
52-Wk Low	$3.17
52-Wk High	$7.50

Market Cap	$328.21M
Volume (M)	341,888.00
52-Wk High	$7.50
52-Wk Low	$3.17

MXCT MaxCyte Inc

About

Feed

News

Sentiment

Earnings

Fundamentals